The ALKBH5 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout population of the ALKBH5 gene in the human HT29 colorectal adenocarcinoma epithelial cell line. This gene-edited model enables loss-of-function investigation of the m6A RNA demethylase ALKBH5, a key regulator of epitranscriptomic dynamics. The polyclonal population preserves the heterogeneous knockout efficiency characteristic of pooled editing, facilitating robust functional screening in a disease-relevant background.
The HT29 parental line originates from a colorectal adenocarcinoma of a 44-year-old female patient and is extensively employed as a model for intestinal epithelial barrier function and colorectal cancer biology. These adherent epithelial cells retain features of enterocytic differentiation and are highly amenable to transfection and gene-editing workflows. Their well-characterized signaling networks, including TGF-?? and hypoxia pathways, provide a physiologically pertinent background for dissecting ALKBH5-dependent mechanisms.
ALKBH5 functions as an m6A eraser by catalyzing the oxidative demethylation of N6-methyladenosine residues in mRNA, counteracting the methyltransferase complex composed of METTL3, METTL14, and WTAP. Its activity is induced under hypoxia by HIF-1?? and can be modulated by TGF-?? signaling, while its expression is also influenced by the transcription factor SOX2. Through demethylation, ALKBH5 reduces the m6A marks on target transcripts such as FOXM1, NANOG, KLF4, MYC, and p21 mRNAs, thereby altering their stability, splicing, and translation efficiency. This post-transcriptional regulation is further mediated by interactions with m6A reader proteins including YTHDF1, YTHDF2, YTHDF3, and the related demethylase FTO.
In the context of colorectal cancer, ALKBH5-mediated m6A demethylation has been implicated in promoting tumor progression, stem cell maintenance, and drug resistance. The HT29 knockout model allows dissection of ALKBH5-dependent gene expression programs that control epithelial cell proliferation, migration, and response to chemotherapeutic agents. Given HT29’s utility in studying epithelial barrier function, these cells also enable examination of how ALKBH5 influences intestinal epithelial integrity and hypoxia-driven adaptations in the tumor microenvironment.
This polyclonal knockout cell population is ideally suited for a broad range of epitranscriptomic studies, including m6A dot blot, m6A-seq, and RNA immunoprecipitation to directly assess changes in RNA modification landscapes. Researchers can employ RT-qPCR and western blotting to validate ALKBH5 loss and monitor expression of downstream targets like FOXM1 and MYC. Functional assays such as colony formation, cell proliferation, and migration/invasion can be utilized to explore the role of ALKBH5 in colorectal cancer cell behavior, while RNA stability measurements link demethylase activity to transcript turnover. For further technical information or customized applications, please contact Ascent Research.
